Immunization using male germ cells and gametes as rich sources of cancer/testis antigens for inhibition of 4T1 breast tumors' growth and metastasis in BALB/c mice-Reference-Cited by-同舟云学术

Immunization using male germ cells and gametes as rich sources of cancer/testis antigens for inhibition of 4T1 breast tumors' growth and metastasis in BALB/c mice

Published:2019-09 Issue: Volume:74 Page:105719
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Safavi Ashkan,Kefayat Amirhosein,Ghahremani Fatemeh,Mahdevar Elham,Moshtaghian Jamal

Funder

Arak University of Medical Sciences

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference66 articles.

1. DNA damage response genes and the development of cancer metastasis;Broustas,2014

2. Multiple Mutations and Cancer;Loeb,2003

3. Hallmarks of Cancer: The Next Generation;Hanahan,2011

4. Revisiting the Hallmarks of Cancer;Fouad,2017

5. Oncogenic Cancer/Testis Antigens: Prime Candidates for Immunotherapy;Gjerstorff,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment;Journal of Functional Biomaterials;2024-08-16

2. Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model;PLOS ONE;2024-06-26

3. Exploring the S Protein of SARS-CoV-2 to Design a Novel Multi-Epitope Vaccine against COVID-19 Based on Immunoinformatics Approaches;Frontiers in Bioscience-Landmark;2024-05-21

4. Design and functional preliminary investigation of recombinant antigen EgG1Y162–EgG1Y162 against Echinococcus granulosus;Open Life Sciences;2023-01-01

5. Epitope-based minigene vaccine targeting fibroblast activation protein α induces specific immune responses and anti-tumor effects in 4 T1 murine breast cancer model;International Immunopharmacology;2022-11